Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCZ696 versus olmesartan for central blood pressure and arterial stiffness in elderly patients with essential hypertension
2012-002899-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential hypertension comparing LCZ696 regimen with Olmesartan regimen (2 arms). Started Dec 2012; status: completed.
02
Drugs
sacubitril + valsartanolmesartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2012-002899-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002899-14.